Despite the promise of increasingly effective pharmacotherapy for obesity, the rate of prescriptions for weight-loss medications in the US is surprisingly low. A study of over 2.2 million adults from 2009 to 2015 found that the rates of rates of prescriptions for anti-obesity medications (AOMs) ranged from 0.6% to 2.9% of eligible patients. The study results also demonstrated an uneven distribution of these prescriptions.
Article Archive
September is National Childhood Obesity Awareness Month. The obesity rate among U.S. youth has steadily increased since the 1990s.
This month's newsletter is written by guest author Sydney Pryor. Sydney is currently a second year PhD student in the Department of Health Policy and Management at The George Washington University Milken Institute School of Public Health where she is also a Graduate Fellow for the Sumner M. Redstone Global Center for Prevention and Wellness.
As the United States begins to wind down from the worst parts of the COVID-19 pandemic, we can begin to take stock of the effects that obesity has had on the outcomes of COVID-19 and the effects of COVID-19 on the prevalence of obesity. In this month’s newsletter, we review what we have learned about both of these impacts.
Effects of Obesity on COVID-19 Outcomes
This month's newsletter is written by guest author Amelia Corl. Amelia recently graduated from The George Washington University’s Milken Institute School of Public Health and is a Research Assistant with the STOP Obesity Alliance. This article was written as a component of the author’s Culminating Experience project titled “A Messaging Framework for Obesity.”
Last year for Mental Health Awareness Month we discussed the intersections of mental health, obesity, and the COVID-19 pandemic. Then, we were focused on the ways lockdowns were affecting mental health.
In January we celebrated the 2-year anniversary of the release of the Lancet Commission on Obesity report, entitled “The Global Syndemic of Obesity, Undernutrition and Climate Change.” The report focuses on the contributions of the food and agriculture, urban design, land use, and transportation systems, and the triple duty solutions to mitigate their contributions to the Global Syndemic. For example, the transportation sector in the U.S.
In March of 2020 we published our first newsletter on the COVID-19 pandemic. At the time, we speculated that people with obesity would be adversely affected by COVID-19. One year and over 2.5 million global deaths later, we know that this is the case.
Recognizing that obesity is a complex, chronic disease affecting more than 2 billion people globally, the STOP Obesity Alliance is a founding partner of the 7th annual Obesity Care Week (OCW), which takes place this year from February 28th – March 6th, 2021.
This month's newsletter is written by guest author Faith Newsome. Faith is currently a first year PhD student at the University of Florida in the Department of Health Outcomes and Biomedical Informatics working on various projects related to obesity research.
This month's newsletter is written by guest author Amelia Corl. Amelia is a graduate student at The George Washington University’s Milken Institute School of Public Health and a Research Assistant with the STOP Obesity Alliance. This article was written as a component of the author’s Applied Practice Experience project titled “The Intersection of Cancer Care and Obesity Care.”
As the COVID-19 pandemic continues to affect countries across the globe, more attention has focused on the link between obesity and severe COVID-19 illness. New guidance by the CDC cautions that even those with a BMI of 25-30 may be at increased risk of severe illness.
On November 2-6, the STOP Obesity Alliance will join the Obesity Society for their 7th annual virtual Obesity Week Interactive.
September is National Childhood Obesity Month. Childhood obesity continues to be a growing problem. About 1 in 5 children in the United States has obesity, and the prevalence among U.S. children aged 2 to 19 years old had risen to 18.5% in 2015-2016.